Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

OvariAn Secretome and Integrated HealthSpan (OASIS)

19 novembre 2026 aggiornato da: Dr. Abigail Goshen, Sheba Medical Center

A Three-Part Study of Ovarian Aging, Circulating Molecular Signatures, and Multidomain Healthspan in Women

The OASIS study aims to identify and characterize circulating molecular signatures associated with ovarian aging, and to determine how these signatures relate to multidomain healthspan during the menopausal transition. The study consists of three parts. Part 1 is a retrospective analysis of existing clinical data and stored biospecimens from approximately 500 women aged 50-85 years. Part 2 is a prospective cohort of 300 women aged 40-50 years who will undergo comprehensive clinical, gynecological, and molecular assessments over 24 months, followed by individualized medical management based on their clinical findings. Part 3 (PRISM) is a nested substudy involving up to 30 women from the prospective cohort who will undergo intensive hormonal and ultrasound monitoring across a single menstrual cycle.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

Background and Purpose:

The menopausal transition is a biologically dynamic period involving changes in ovarian reserve, endocrine function, and morphology that parallel shifts in body composition, bone, cardiovascular, metabolic, sleep, and cognitive health. Because conventional endocrine markers (estradiol, FSH, LH, AMH) do not provide a complete molecular readout of ovarian biology across this transition, OASIS will establish an integrated biological framework linking ovarian aging with systemic molecular physiology using advanced multi-omics profiling.

Part 1: Retrospective OASIS Biobank Cohort This phase includes approximately 500 women aged 50-85 years who previously participated in research at Sheba Medical Center and signed the applicable Biobank consent. The study utilizes existing coded demographic, clinical, and lifestyle data, alongside stored plasma samples. No new patient contact or procedures are required.

Part 2: Prospective OASIS Cohort

This phase will enroll 300 women aged 40-50 years. Participants will complete three study visits over two years:

Baseline (Month 0) and Month 12: Comprehensive multidomain clinical assessment, standardized gynecological evaluation, transvaginal ultrasound (uterus and ovaries), and biospecimen collection for clinical testing and biospecimen banking.

Month 24: A limited follow-up visit including a medical update, the Menopause Rating Scale (MRS) and selected questionnaires, fasting reproductive-hormone testing (including AMH), biospecimen collection, and a gynecological/ultrasound assessment.

Clinical Management: Following the baseline visit, participants will receive their validated clinical results, a medical summary, and individualized recommendations. Management is tailored to the participant's specific clinical findings and may include lifestyle modifications and consideration of Hormone Replacement Therapy/Menopausal Hormone Therapy (HRT/MHT) when clinically indicated.

Part 3: PRISM Nested Intensive Substudy (Precision Reproductive Imaging and Secretome Monitoring) Participation in PRISM is optional and requires separate informed consent. Up to 30 women from Part 2 may participate in up to four additional visits, separate from the main OASIS baseline visit, during a single menstrual cycle.

Tipo di studio

Osservativo

Iscrizione (Stimato)

800

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israele, 5262000
        • Sheba Medical Center
        • Contatto:
          • Abigail Goshen
          • Numero di telefono: 972542270050
        • Investigatore principale:
          • Abigail Goshen, PhD
        • Investigatore principale:
          • Lauren Petrick, PhD
        • Sub-investigatore:
          • Yaron Rabinovici, Dr

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Femmina

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Part 1, retrospective biobank cohort: women aged 50 years and above Parts 2 and 3, prospective main cohort and nested PRISM cohort: women aged 40-50 years

Descrizione

Inclusion Criteria:

  • Women aged 50-85 years at enrollment (for part 1 retrospective study). or
  • Women aged 40-50 years at enrollment (for part 2 prospective study).
  • Able to understand the study information and provide written informed consent.
  • Able and willing to complete the study assessments and follow-up visits.

Part 3 (PRISM substudy) specific criteria:

  • Natural, regular menstruation.
  • Reported menstrual-cycle length of 21-35 days.
  • Willing and able to attend four additional blood-draw and transvaginal ultrasound visits across one menstrual cycle.
  • Signed separate PRISM informed consent.
  • Not using oral contraceptives, other hormonal contraceptives, menopausal hormone therapy, or another hormonal treatment at PRISM enrollment.

Exclusion Criteria:

  • A former diagnosis of significant cognitive reduction (MoCA score <24).
  • Former diagnosis of a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, or Lewy body dementia.
  • Former diagnosis of psychiatric disease.
  • Underwent chemotherapy or radiation therapy in the past two years.

Part 3 (PRISM substudy) specific criteria:

  • Failure to meet the PRISM inclusion criteria.
  • Unwillingness or inability to sign the PRISM consent.
  • Irregular cycle or reported cycle length outside 21-35 days.
  • Current hormonal contraceptive, menopausal hormone therapy or other hormonal treatment.
  • Inability or unwillingness to undergo repeated blood draws.
  • Inability or unwillingness to undergo transvaginal ultrasound.
  • A medical condition that, in the investigator's judgment, makes participation unsafe or unsuitable.
  • A medical, technical, or logistical reason that precludes reliable completion of the substudy.
  • Pregnancy, breastfeeding, initiation of hormonal treatment, or a significant medical change during PRISM must be reported to the study team and may lead to discontinuation at the Principal Investigator's discretion.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Coorti e interventi

Gruppo / Coorte
Part 1: Retrospective Biobank Cohort

500 women aged 50 years and older with available clinical data and stored biospecimens from the Sheba Biobank. Evaluation is limited to retrospective data extraction and molecular analysis.

Part 2: Prospective Main Cohort

300 women aged 40-50 years undergo longitudinal clinical, multidomain, and gynecological assessments at Baseline, Month 12, and Month 24, and provide biosamples. Participants receive individualized clinical management (including potential HRT/MHT) based on the clinical findings.

Part 3: PRISM Nested Substudy

Up to 30 women co-enrolled from Part 2. Participants undergo intensive repeated measures (transvaginal ultrasound and blood sampling for hormone/molecular analysis) across up to four visits during a single menstrual cycle to assess short-term longitudinal changes.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Reproductive hormone concentrations
Lasso di tempo: Baseline, 12 months, 24 months

The concentrations of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone will be measured in blood samples.

Baseline, 12 months, 24 months
Antral Follicle Count (AFC)
Lasso di tempo: Baseline, 12 months, 24 months

The total number of antral follicles in both ovaries will be assessed using transvaginal ultrasound.

Baseline, 12 months, 24 months
Total ovarian volume
Lasso di tempo: Baseline, 12 months, 24 months

Ovarian volume in milliliters will be measured using transvaginal ultrasound. Total ovarian volume will be calculated based on measurements of both ovaries.

Baseline, 12 months, 24 months
Number of participants with abnormal ovarian or adnexal ultrasound findings
Lasso di tempo: Baseline, 12 months, 24 months

The number and proportion of participants with abnormal ovarian morphology, ovarian cysts, or other abnormal adnexal findings identified by transvaginal ultrasound will be recorded.

Baseline, 12 months, 24 months
Circulating ovarian-associated molecular signature
Lasso di tempo: Baseline, 12 months

Plasma protein levels will be assessed using high-throughput proteomic profiling with the Olink Explore HT platform to characterize circulating molecular signatures associated with ovarian function.

Baseline, 12 months
Montreal Cognitive Assessment (MoCA) score
Lasso di tempo: Baseline, 12 months

Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

Baseline, 12 months
Apnea-Hypopnea Index (AHI)
Lasso di tempo: Baseline, 12 months

Sleep apnea severity will be assessed by measuring the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of sleep.

Baseline, 12 months
Glycated hemoglobin (HbA1c)
Lasso di tempo: Baseline, 12 months

Glycemic control will be assessed by measuring the percentage of glycated hemoglobin (HbA1c) in blood samples.

Baseline, 12 months
DXA-derived body composition
Lasso di tempo: Baseline, 12 months

Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measurements of fat mass and lean mass (kg).

Baseline, 12 months
Bone mineral density (BMD)
Lasso di tempo: Baseline, 12 months

Bone mineral density (BMD) will be measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip. Results will be reported in g/cm².

Baseline, 12 months
Handgrip strength
Lasso di tempo: Baseline, 12 months

Physical function will be assessed by measuring handgrip strength using a calibrated hand dynamometer. Results will be reported in kilograms (kg).

Baseline, 12 months
Pulse wave velocity (PWV)
Lasso di tempo: Baseline, 12 months

Arterial stiffness will be assessed by measuring pulse wave velocity (PWV). Results will be reported in meters per second (m/s).

Baseline, 12 months
Within-woman changes in reproductive endocrine measures
Lasso di tempo: Up to four sampling time points during the first month of the study

Serial measurements of AMH, FSH, LH, estradiol, and progesterone concentrations in blood samples will be performed to assess short-term hormonal fluctuations within participants.

Up to four sampling time points during the first month of the study

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Abigail Goshen, PhD, Sheba Medical Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

2 novembre 2026

Completamento primario (Stimato)

1 novembre 2029

Completamento dello studio (Stimato)

1 maggio 2030

Date di iscrizione allo studio

Primo inviato

22 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

19 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 3577-26-SMC
  • OD-2026001 (Altro numero di sovvenzione/finanziamento: Nuttall Women's Health (NWH))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .